SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer - Prova Education

ReachMD Healthcare Image

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

How Antibody-Based Therapies Are Revolutionizing Its Management
How Antibody-Based Therapies Are Revolutionizing Its Management
CME/CE
How Antibody-Based Therapies Are Revolutionizing Its Management
0.25 credits
- Caroline Piatek, MD
- Irina Murakhovskaya, MD
0.25 credits
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
MinuteCE®
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
MinuteCE®
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits